Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 2: | Line 2: | ||
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=592508 NCI Drug Dictionary]: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases. | ||
| − | ==Diseases for which it is established== | + | ==Diseases for which it is established ''(work in progress)''== |
*[[Hepatocellular carcinoma]] | *[[Hepatocellular carcinoma]] | ||
| Line 13: | Line 13: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' YN-968D1 |
*'''Generic name:''' rivoceranib | *'''Generic name:''' rivoceranib | ||
*'''Brand name:''' Aitan | *'''Brand name:''' Aitan | ||
Latest revision as of 02:08, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is established (work in progress)
Diseases for which it is used
- Esophageal cancer
- Gastric cancer
- Non-small cell lung cancer, EGFR-mutated
- Thyroid cancer, differentiated
Also known as
- Code name: YN-968D1
- Generic name: rivoceranib
- Brand name: Aitan